1
|
Camci M, Karali N. Bioisosterism: 1,2,4-Oxadiazole Rings. ChemMedChem 2023; 18:e202200638. [PMID: 36772857 DOI: 10.1002/cmdc.202200638] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2022] [Revised: 02/10/2023] [Accepted: 02/10/2023] [Indexed: 02/12/2023]
Abstract
Although studies in drug discovery have gained momentum in recent years, the conversion of drugs in use today into less toxic derivatives with pharmacologically superior properties is still of great importance in drug research. Bioisosterism facilitates the conversion of drugs into derivatives that present more positive pharmacological and toxicological profiles by changing existing groups in the drug structure within the framework of certain criteria that have been expanded today. The 1,2,4-oxadiazole ring is used as a bioisostere for ester and amide groups due to its resistance to hydrolysis. However, this ring is not limited to esters and amides, but can also be used as a bioisostere for other functional groups. In this review, cases in which the 1,2,4-oxadiazole ring is used as a bioisostere for various functional groups are discussed. Herein we shed light on 1,2,4-oxadiazole bioisosterism in the development of new drug candidates and in enhancing the pharmacological profiles of currently available drugs.
Collapse
Affiliation(s)
- Merve Camci
- Istanbul University, Faculty of Pharmacy Department of Pharmaceutical Chemistry, 34134 Beyazıt, Istanbul, Turkey
| | - Nilgün Karali
- Istanbul University, Faculty of Pharmacy Department of Pharmaceutical Chemistry, 34134 Beyazıt, Istanbul, Turkey
| |
Collapse
|
2
|
3-(3,4-Dichlorophenyl)-5-(1H-indol-5-yl)-1,2,4-oxadiazole. MOLBANK 2023. [DOI: 10.3390/m1552] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023] Open
Abstract
3-(3,4-Dichlorophenyl)-5-(1H-indol-5-yl)-1,2,4-oxadiazole was synthesized via the condensation of 3,4-dichlorobenzamidoxime and methyl 1H-indole-5-carboxylate using a superbasic medium (NaOH/DMSO). The compound was tested as a potential inhibitor of human monoamine oxidase (MAO) A and B. It demonstrated a notable inhibition with an IC50 value of 0.036 μM for the MAO-B and isoform specificity. The product was characterized by 1H-NMR, 13C-NMR, and HRMS. In conclusion, the new active MAO-B inhibitor may serve as a candidate for the future discovery of therapeutic agents for neurodegenerative disorders such as Parkinson’s disease.
Collapse
|
3
|
Zhang YY, Li L, Zhang XZ, Peng JB. Brønsted acid catalyzed remote C6 functionalization of 2,3-disubstituted indoles with β,γ-unsaturated α-ketoester. Front Chem 2022; 10:992398. [PMID: 36176896 PMCID: PMC9513241 DOI: 10.3389/fchem.2022.992398] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2022] [Accepted: 08/09/2022] [Indexed: 12/03/2022] Open
Abstract
A metal-free catalytic approach for the remote C6-functionalization of 2,3-disubstituted indoles has been developed. In the presence of catalytic amounts of Brønsted acid, the β,γ-unsaturated α-ketoesters react with 2,3-disubstituted indoles at the C6 position selectively. Under mild reaction conditions, a range of C6-functionalized indoles were prepared with good yields and excellent regioselectivity. This methodology provides a concise and efficient route for the synthesis of C6-functionalized indole derivatives.
Collapse
|
4
|
Świątek P, Glomb T, Dobosz A, Gębarowski T, Wojtkowiak K, Jezierska A, Panek JJ, Świątek M, Strzelecka M. Biological Evaluation and Molecular Docking Studies of Novel 1,3,4-Oxadiazole Derivatives of 4,6-Dimethyl-2-sulfanylpyridine-3-carboxamide. Int J Mol Sci 2022; 23:ijms23010549. [PMID: 35008977 PMCID: PMC8745710 DOI: 10.3390/ijms23010549] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2021] [Revised: 12/30/2021] [Accepted: 12/31/2021] [Indexed: 02/06/2023] Open
Abstract
To date, chronic inflammation is involved in most main human pathologies such as cancer, and autoimmune, cardiovascular or neurodegenerative disorders. Studies suggest that different prostanoids, especially prostaglandin E2, and their own synthase (cyclooxygenase enzyme-COX) can promote tumor growth by activating signaling pathways which control cell proliferation, migration, apoptosis, and angiogenesis. Non-steroidal anti-inflammatory drugs (NSAIDs) are used, alongside corticosteroids, to treat inflammatory symptoms particularly in all chronic diseases. However, their toxicity from COX inhibition and the suppression of physiologically important prostaglandins limits their use. Therefore, in continuation of our efforts in the development of potent, safe, non-toxic chemopreventive compounds, we report herein the design, synthesis, biological evaluation of new series of Schiff base-type hybrid compounds containing differently substituted N-acyl hydrazone moieties, 1,3,4-oxadiazole ring, and 4,6-dimethylpyridine core. The anti-COX-1/COX-2, antioxidant and anticancer activities were studied. Schiff base 13, containing 2-bromobenzylidene residue inhibited the activity of both isoenzymes, COX-1 and COX-2 at a lower concentration than standard drugs, and its COX-2/COX-1 selectivity ratio was similar to meloxicam. Furthermore, the results of cytotoxicity assay indicated that all of the tested compounds exhibited potent anti-cancer activity against A549, MCF-7, LoVo, and LoVo/Dx cell lines, compared with piroxicam and meloxicam. Moreover, our experimental study was supported by density functional theory (DFT) and molecular docking to describe the binding mode of new structures to cyclooxygenase.
Collapse
Affiliation(s)
- Piotr Świątek
- Department of Medicinal Chemistry, Faculty of Pharmacy, Wroclaw Medical University, Borowska 211, 50-556 Wroclaw, Poland;
- Correspondence: (P.Ś.); (T.G.); Tel.: +48-717840391 (P.Ś. & T.G.)
| | - Teresa Glomb
- Department of Medicinal Chemistry, Faculty of Pharmacy, Wroclaw Medical University, Borowska 211, 50-556 Wroclaw, Poland;
- Correspondence: (P.Ś.); (T.G.); Tel.: +48-717840391 (P.Ś. & T.G.)
| | - Agnieszka Dobosz
- Department of Medical Science Foundation, Faculty of Pharmacy, Wroclaw Medical University, Borowska 211, 50-556 Wroclaw, Poland;
| | - Tomasz Gębarowski
- Department of Biostructure and Animal Physiology, Wroclaw University of Environmental and Life Sciences, Kożuchowska 1/3, 51-631 Wroclaw, Poland;
| | - Kamil Wojtkowiak
- Faculty of Chemistry, University of Wroclaw, F. Joliot-Curie 14, 50-383 Wrocław, Poland; (K.W.); (A.J.); (J.J.P.)
| | - Aneta Jezierska
- Faculty of Chemistry, University of Wroclaw, F. Joliot-Curie 14, 50-383 Wrocław, Poland; (K.W.); (A.J.); (J.J.P.)
| | - Jarosław J. Panek
- Faculty of Chemistry, University of Wroclaw, F. Joliot-Curie 14, 50-383 Wrocław, Poland; (K.W.); (A.J.); (J.J.P.)
| | - Małgorzata Świątek
- Hospital Pharmacy, University Clinical Hospital, Borowska 213, 50-556 Wrocław, Poland;
| | - Małgorzata Strzelecka
- Department of Medicinal Chemistry, Faculty of Pharmacy, Wroclaw Medical University, Borowska 211, 50-556 Wroclaw, Poland;
| |
Collapse
|
5
|
Yavari I, Amirahmadi A, Halvagar MR. Formation of 1,2,4-oxadiazole derivatives from Erlenmeyer azlactones and amidoximes. MONATSHEFTE FUR CHEMIE 2019. [DOI: 10.1007/s00706-019-02486-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
6
|
Xu C, Xu J. Oxygenophilic Lewis Acid Promoted Synthesis of 2-Arylindoles from Anilines and Cyanoepoxides in Alcohol. J Org Chem 2018; 83:14733-14742. [DOI: 10.1021/acs.joc.8b02203] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Chuangchuang Xu
- State Key Laboratory of Chemical Resource Engineering, Department of Organic Chemistry, Faculty of Science, Beijing University of Chemical Technology, Beijing 100029, People’s Republic of China
| | - Jiaxi Xu
- State Key Laboratory of Chemical Resource Engineering, Department of Organic Chemistry, Faculty of Science, Beijing University of Chemical Technology, Beijing 100029, People’s Republic of China
| |
Collapse
|
7
|
Purushotham N, Poojary B. An Expeditious Synthesis of Chiral 1,2,4-Oxadiazole Peptidomimetics from Heteroaroyl Monopeptides. ChemistrySelect 2018. [DOI: 10.1002/slct.201801921] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- Nikil Purushotham
- Department of Chemistry; Mangalore University, Mangalagangothri-; 574 199 Karnataka India
| | - Boja Poojary
- Department of Chemistry; Mangalore University, Mangalagangothri-; 574 199 Karnataka India
| |
Collapse
|
8
|
Lauder K, Toscani A, Scalacci N, Castagnolo D. Synthesis and Reactivity of Propargylamines in Organic Chemistry. Chem Rev 2017; 117:14091-14200. [PMID: 29166000 DOI: 10.1021/acs.chemrev.7b00343] [Citation(s) in RCA: 282] [Impact Index Per Article: 40.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Propargylamines are a versatile class of compounds which find broad application in many fields of chemistry. This review aims to describe the different strategies developed so far for the synthesis of propargylamines and their derivatives as well as to highlight their reactivity and use as building blocks in the synthesis of chemically relevant organic compounds. In the first part of the review, the different synthetic approaches to synthesize propargylamines, such as A3 couplings and C-H functionalization of alkynes, have been described and organized on the basis of the catalysts employed in the syntheses. Both racemic and enantioselective approaches have been reported. In the second part, an overview of the transformations of propargylamines into heterocyclic compounds such as pyrroles, pyridines, thiazoles, and oxazoles, as well as other relevant organic derivatives, is presented.
Collapse
Affiliation(s)
- Kate Lauder
- School of Cancer and Pharmaceutical Sciences, King's College London , Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, United Kingdom
| | - Anita Toscani
- School of Cancer and Pharmaceutical Sciences, King's College London , Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, United Kingdom
| | - Nicolò Scalacci
- School of Cancer and Pharmaceutical Sciences, King's College London , Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, United Kingdom
| | - Daniele Castagnolo
- School of Cancer and Pharmaceutical Sciences, King's College London , Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, United Kingdom
| |
Collapse
|
9
|
Mali JK, Takale BS, Telvekar VN. Readily switchable one-pot 5-exo-dig cyclization using a palladium catalyst. RSC Adv 2017. [DOI: 10.1039/c6ra25857c] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
A convenient, ligand-free, Pd(OAc)2-catalyzed one-pot reaction has been developed for the synthesis of oxazolines and oxazoles from easily available acid chlorides and propargylamine.
Collapse
Affiliation(s)
- Jaishree K. Mali
- Department of Pharmaceutical Sciences and Technology
- Institute of Chemical Technology
- Mumbai 400 019
- India
| | - Balaram S. Takale
- Department of Pharmaceutical Sciences and Technology
- Institute of Chemical Technology
- Mumbai 400 019
- India
| | - Vikas. N. Telvekar
- Department of Pharmaceutical Sciences and Technology
- Institute of Chemical Technology
- Mumbai 400 019
- India
| |
Collapse
|
10
|
De Lucca GV, Shi Q, Liu Q, Batt DG, Beaudoin Bertrand M, Rampulla R, Mathur A, Discenza L, D’Arienzo C, Dai J, Obermeier M, Vickery R, Zhang Y, Yang Z, Marathe P, Tebben AJ, Muckelbauer JK, Chang CJ, Zhang H, Gillooly K, Taylor T, Pattoli MA, Skala S, Kukral DW, McIntyre KW, Salter-Cid L, Fura A, Burke JR, Barrish JC, Carter PH, Tino JA. Small Molecule Reversible Inhibitors of Bruton’s Tyrosine Kinase (BTK): Structure–Activity Relationships Leading to the Identification of 7-(2-Hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177). J Med Chem 2016; 59:7915-35. [DOI: 10.1021/acs.jmedchem.6b00722] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Affiliation(s)
- George V. De Lucca
- Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Qing Shi
- Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Qingjie Liu
- Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Douglas G. Batt
- Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Myra Beaudoin Bertrand
- Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Rick Rampulla
- Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Arvind Mathur
- Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Lorell Discenza
- Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Celia D’Arienzo
- Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Jun Dai
- Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Mary Obermeier
- Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Rodney Vickery
- Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Yingru Zhang
- Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Zheng Yang
- Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Punit Marathe
- Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Andrew J. Tebben
- Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Jodi K. Muckelbauer
- Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - ChiehYing J. Chang
- Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Huiping Zhang
- Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Kathleen Gillooly
- Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Tracy Taylor
- Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Mark A. Pattoli
- Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Stacey Skala
- Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Daniel W. Kukral
- Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Kim W. McIntyre
- Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Luisa Salter-Cid
- Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Aberra Fura
- Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - James R. Burke
- Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Joel C. Barrish
- Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Percy H. Carter
- Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Joseph A. Tino
- Immunosciences Discovery Chemistry, ‡Immunoscience Discovery Biology, §Molecular Structure
and Design, Molecular Discovery Technologies, ∥Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, and ⊥ECTR/CTTO Imaging Department, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| |
Collapse
|
11
|
Howard KT, Chisholm JD. Preparation and Applications of 4-Methoxybenzyl Esters in Organic Synthesis. ORG PREP PROCED INT 2016; 48:1-36. [PMID: 27546912 DOI: 10.1080/00304948.2016.1127096] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Affiliation(s)
- Kyle T Howard
- Department of Chemistry, 1-014 Center for Science & Technology, Syracuse University, Syracuse, NY 13244, USA
| | - John D Chisholm
- Department of Chemistry, 1-014 Center for Science & Technology, Syracuse University, Syracuse, NY 13244, USA
| |
Collapse
|
12
|
Liu Q, Batt DG, Lippy JS, Surti N, Tebben AJ, Muckelbauer JK, Chen L, An Y, Chang C, Pokross M, Yang Z, Wang H, Burke JR, Carter PH, Tino JA. Design and synthesis of carbazole carboxamides as promising inhibitors of Bruton’s tyrosine kinase (BTK) and Janus kinase 2 (JAK2). Bioorg Med Chem Lett 2015; 25:4265-9. [DOI: 10.1016/j.bmcl.2015.07.102] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2015] [Revised: 07/27/2015] [Accepted: 07/29/2015] [Indexed: 11/30/2022]
|
13
|
|
14
|
|
15
|
Gulevich AV, Dudnik AS, Chernyak N, Gevorgyan V. Transition metal-mediated synthesis of monocyclic aromatic heterocycles. Chem Rev 2013; 113:3084-213. [PMID: 23305185 PMCID: PMC3650130 DOI: 10.1021/cr300333u] [Citation(s) in RCA: 803] [Impact Index Per Article: 73.0] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Affiliation(s)
- Anton V. Gulevich
- Department of Chemistry, University of Illinois at Chicago, 845 West Taylor Street, 4500 SES, M/C 111, Chicago, Illinois 60607-7061
| | - Alexander S. Dudnik
- Department of Chemistry, University of Illinois at Chicago, 845 West Taylor Street, 4500 SES, M/C 111, Chicago, Illinois 60607-7061
| | - Natalia Chernyak
- Department of Chemistry, University of Illinois at Chicago, 845 West Taylor Street, 4500 SES, M/C 111, Chicago, Illinois 60607-7061
| | - Vladimir Gevorgyan
- Department of Chemistry, University of Illinois at Chicago, 845 West Taylor Street, 4500 SES, M/C 111, Chicago, Illinois 60607-7061
| |
Collapse
|
16
|
Synthesis and biological evaluation of new cytotoxic indazolo[4,3-gh]isoquinolinone derivatives. Bioorg Med Chem Lett 2013; 23:1846-52. [DOI: 10.1016/j.bmcl.2013.01.022] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2012] [Revised: 01/02/2013] [Accepted: 01/04/2013] [Indexed: 11/20/2022]
|
17
|
Tran-Dubé M, Johnson S, McAlpine I. A two-step, one-pot procedure using acid chlorides and propargyl amines to form tri-substituted oxazoles via gold-catalyzed cyclization. Tetrahedron Lett 2013. [DOI: 10.1016/j.tetlet.2012.11.013] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
18
|
Szalata C, Szymoniak J, Fabis F, Butt-Gueulle S, Rault S, Bertus P, Gérard S, Sapi J. Cyclopropyl-tryptamine analogues: synthesis and biological evaluation as 5-HT(6) receptor ligands. ChemMedChem 2012; 8:70-3. [PMID: 23129513 DOI: 10.1002/cmdc.201200396] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2012] [Indexed: 11/06/2022]
Abstract
Conformational restrictions: Based on the pharmacophore model for 5-HT(6) receptor ligands (shown), tryptamine analogues bearing a cyclopropyl ring on the α-position of the tryptamine side chain were synthesized and evaluated against 5-HT receptors. N,N-Dimethyl-1-arylsulfonyltryptamine derivatives exhibited promising selectivity for 5-HT(6) over 5-HT(1a) and 5-HT(4) receptors and interesting activity against 5-HT(6) (K(i) =∼0.15 μM; IC(50) =∼0.20 μM).
Collapse
Affiliation(s)
- Claude Szalata
- Institut de Chimie Moléculaire de Reims, UMR CNRS 7312 (ex 6229), Faculté de Pharmacie, Université de Reims-Champagne-Ardenne, 51096 Reims Cedex and UFR Sciences, 51687, Reims Cedex 2, France
| | | | | | | | | | | | | | | |
Collapse
|
19
|
Hamada Y, Kiso Y. The application of bioisosteres in drug design for novel drug discovery: focusing on acid protease inhibitors. Expert Opin Drug Discov 2012; 7:903-22. [PMID: 22873630 DOI: 10.1517/17460441.2012.712513] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
INTRODUCTION A bioisostere is a powerful concept for medicinal chemistry. It allows the improvement of the stability; oral absorption; membrane permeability; and absorption, distribution, metabolism and excretion (ADME) of drug candidate, while retaining their biological properties. The term 'bioisostere' is derived from 'isostere', whose physical and chemical properties, such as steric size, hydrophobicity, and electronegativity, are similar to those of a functional or atomic group, and is considered to possess biological properties. Here, the authors highlight the recent applications of bioisosteres in drug design, mainly based on our drug discovery studies. AREAS COVERED This review discusses the application of bioisosteres for novel drug discovery with focus on the authors' drug discovery studies such as renin, HIV-protease, and β-secretase inhibitors. The authors highlight that some bioisosteres can form the scaffolding for drug candidates, namely substrate transition state, amide/ester, and carboxylic acid bioisosteres. Moreover, the authors propose the new terms 'electron-donor bioisostere' and 'conformational bioisostere' for drug discovery. EXPERT OPINION The authors discuss the importance of bioisostere's design concept based on specific interaction with the corresponding biomolecule. In addition, some strategies for drug discovery based on the bioisostere concept are introduced. Many bioisosteres, which are recognized by corresponding target biomolecules as exhibiting similar biological properties, have been reported to date; most of the recently developed bioisosteres were designed by cheminformatics approaches. Some molecular design softwares and databases are introduced.
Collapse
Affiliation(s)
- Yoshio Hamada
- Faculty of Pharmaceutical Sciences , Kobe Gakuin University, Minatojima, Chuo-ku, Kobe, Japan
| | | |
Collapse
|
20
|
Hashmi ASK, Littmann A. Gold Catalysis: One-Pot Alkylideneoxazoline Synthesis/Alder-Ene Reaction. Chem Asian J 2012; 7:1435-42. [DOI: 10.1002/asia.201200046] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2012] [Revised: 02/18/2012] [Indexed: 11/09/2022]
|
21
|
Li S, Li Z, Yuan Y, Peng D, Li Y, Zhang L, Wu Y. Au(I)-Catalyzed Intramolecular Hydroamination of the Fluorinated N′-Aryl-N-Propargyl Amidines: Mild Conditions for the Synthesis of 2-Fluoroalkyl Imidazole Derivatives. Org Lett 2012; 14:1130-3. [DOI: 10.1021/ol3000525] [Citation(s) in RCA: 52] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Shan Li
- Key Laboratory of Organofluorine Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 345 Lingling Road, Shanghai 200032, China, and School of Chemistry and Chemical Engineering, Huazhong University of Science and Technology, 1037 Luoyu Road, Wuhan, Hubei 430074, China
| | - Zhengke Li
- Key Laboratory of Organofluorine Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 345 Lingling Road, Shanghai 200032, China, and School of Chemistry and Chemical Engineering, Huazhong University of Science and Technology, 1037 Luoyu Road, Wuhan, Hubei 430074, China
| | - Yafen Yuan
- Key Laboratory of Organofluorine Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 345 Lingling Road, Shanghai 200032, China, and School of Chemistry and Chemical Engineering, Huazhong University of Science and Technology, 1037 Luoyu Road, Wuhan, Hubei 430074, China
| | - Dongjie Peng
- Key Laboratory of Organofluorine Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 345 Lingling Road, Shanghai 200032, China, and School of Chemistry and Chemical Engineering, Huazhong University of Science and Technology, 1037 Luoyu Road, Wuhan, Hubei 430074, China
| | - Yajun Li
- Key Laboratory of Organofluorine Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 345 Lingling Road, Shanghai 200032, China, and School of Chemistry and Chemical Engineering, Huazhong University of Science and Technology, 1037 Luoyu Road, Wuhan, Hubei 430074, China
| | - Lisi Zhang
- Key Laboratory of Organofluorine Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 345 Lingling Road, Shanghai 200032, China, and School of Chemistry and Chemical Engineering, Huazhong University of Science and Technology, 1037 Luoyu Road, Wuhan, Hubei 430074, China
| | - Yongming Wu
- Key Laboratory of Organofluorine Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 345 Lingling Road, Shanghai 200032, China, and School of Chemistry and Chemical Engineering, Huazhong University of Science and Technology, 1037 Luoyu Road, Wuhan, Hubei 430074, China
| |
Collapse
|
22
|
Brandt SD, Moore SA, Freeman S, Kanu AB. Characterization of the synthesis of N,N-dimethyltryptamine by reductive amination using gas chromatography ion trap mass spectrometry. Drug Test Anal 2010; 2:330-8. [DOI: 10.1002/dta.142] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
|
23
|
Burns AR, Kerr JH, Kerr WJ, Passmore J, Paterson LC, Watson AJB. Tuned methods for conjugate addition to a vinyl oxadiazole; synthesis of pharmaceutically important motifs. Org Biomol Chem 2010; 8:2777-83. [DOI: 10.1039/c001772h] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
24
|
Hugel HM, Kennaway DJ. SYNTHESIS AND CHEMISTRY OF MELATONIN AND OF RELATED COMPOUNDS. A REVIEW. ORG PREP PROCED INT 2009. [DOI: 10.1080/00304949509458177] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
25
|
Raoul M, Patigny D, Fabis F, Dauphin F, Rault S, Sapi J, Laronze JY. N-Arylsulfonyl-2-vinyltryptamines as new 5-HT6serotonin receptor Ligands. J Enzyme Inhib Med Chem 2008; 21:251-60. [PMID: 16918072 DOI: 10.1080/14756360600700285] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
Abstract
Several new 2-vinyl-Nb,Nb-dimethyltryptamines were prepared using Fischer indole synthesis followed by simple functional group transformations and evaluated on 5-HT4, 5-HT5, 5-HT6 and 5-HT7 serotonin receptors. It was found that 2-vinyl substitution conferred a potent and selective 5-HT6 binding activity to these molecules which could be enhanced by Na-arylsulfonyl substituents.
Collapse
Affiliation(s)
- Marion Raoul
- FRE CNRS 2715 Isolement, Structure, Transformations et Synthise de Substances Naturelles, IFR 53 Biomolicules, Faculté de Pharmacie, Université de Reims-Champagne-Ardenne, 51 rue Cognacq-Jay, Reims, France
| | | | | | | | | | | | | |
Collapse
|
26
|
Bidylo TI, Yurovskaya MA. Synthesis of tryptamines by the Fischer method using synthetic precursors and latent forms of amino-butanal (review). Chem Heterocycl Compd (N Y) 2008. [DOI: 10.1007/s10593-008-0057-x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
27
|
England DB, Padwa A. Gold-Catalyzed Cycloisomerization of N-Propargylindole-2-carboxamides: Application toward the Synthesis of Lavendamycin Analogues. Org Lett 2008; 10:3631-4. [DOI: 10.1021/ol801385h] [Citation(s) in RCA: 111] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Dylan B. England
- Department of Chemistry, Emory University, Atlanta, Georgia 30322
| | - Albert Padwa
- Department of Chemistry, Emory University, Atlanta, Georgia 30322
| |
Collapse
|
28
|
Shutske GM. Patent Update: Central & Peripheral Nervous System: Recent patent activity relating to serotonin pharmacology. Expert Opin Ther Pat 2008. [DOI: 10.1517/13543776.4.10.1233] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
29
|
Central & Peripheral Nervous Systems: Substituted piperazines for the treatment of migraine. Expert Opin Ther Pat 2008. [DOI: 10.1517/13543776.5.12.1317] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
30
|
Zefirova ON, Zefirov NS. Physiologically active compounds interacting with serotonin (5-hydroxytryptamine) receptors. RUSSIAN CHEMICAL REVIEWS 2007. [DOI: 10.1070/rc2001v070n04abeh000654] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
31
|
Affiliation(s)
- Guy R Humphrey
- Department of Process Research, Merck & Co., Inc., Rahway, New Jersey 07065, USA.
| | | |
Collapse
|
32
|
Terzioglu N, Höltje HD. Receptor-Based 3D QSAR Analysis of Serotonin 5-HT1D Receptor Agonists. ACTA ACUST UNITED AC 2005. [DOI: 10.1135/cccc20051482] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
A three-dimensional quantitative structure-activity relationship study (3D QSAR) has been successfully applied to explain the binding affinities for the serotonin 5-HT1D receptor of a triptan series. The paper describes the development of a receptor-based 3D QSAR model of some known agonists and recently developed triptans on the 5-HT1D serotonergic receptor, showing a significant correlation between predicted and experimentally measured binding affinity (pIC50). The pIC50 values of these agonists are in the range from 5.40 to 9.50. The ligand alignment obtained from dynamic simulations was taken as basis for a 3D QSAR analysis applying the GRID/GOLPE program. 3D QSAR analysis of the ligands resulted in a model of high quality (r2 = 0.9895, q2LOO = 0.7854). This is an excellent result and proves both the validity of the proposed pharmacophore and the predictive quality of the 3D QSAR model for the triptan series of serotonin 5-HT1D receptor agonists.
Collapse
|
33
|
Verma RP, Kurup A, Hansch C. On the role of polarizability in QSAR. Bioorg Med Chem 2005; 13:237-55. [PMID: 15582468 DOI: 10.1016/j.bmc.2004.09.039] [Citation(s) in RCA: 72] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2004] [Revised: 09/22/2004] [Accepted: 09/22/2004] [Indexed: 11/29/2022]
Abstract
The polarizability of a molecule, an important physical property, is currently attracting our attention particularly in the area of QSAR for chemical-biological interactions. In this report, the polarizability effects on ligand-substrate interactions has been discussed in terms of NVE (number of valence electrons) using additive values for valence electrons and the formulation of a total number of 51 QSAR. The QSAR model can be illustrated by Eq. I. log 1/C = a(NVE) +/- constant
Collapse
|
34
|
Kuduk SD, Ng C, Feng DM, Wai JMC, Chang RSL, Harrell CM, Murphy KL, Ransom RW, Reiss D, Ivarsson M, Mason G, Boyce S, Tang C, Prueksaritanont T, Freidinger RM, Pettibone DJ, Bock MG. 2,3-Diaminopyridine Bradykinin B1 Receptor Antagonists. J Med Chem 2004; 47:6439-42. [PMID: 15588075 DOI: 10.1021/jm049394l] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Bradykinin B1 receptor antagonists embody a potentially novel approach for the treatment of chronic pain and inflammation. A series of 2,3-diaminopyridine B1 antagonists was optimized to have sub-nanomolar affinity and good pharmacokinetic properties. Lead compounds were shown to exhibit good efficacy in rabbit in vivo models of pain and inflammation.
Collapse
Affiliation(s)
- Scott D Kuduk
- Department of Medicinal Chemistry, Merck Research Laboratories, PO Box 4, West Point, Pennsylvania 19486, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Hashmi ASK, Weyrauch JP, Frey W, Bats JW. Gold Catalysis: Mild Conditions for the Synthesis of Oxazoles from N-Propargylcarboxamides and Mechanistic Aspects. Org Lett 2004; 6:4391-4. [PMID: 15524491 DOI: 10.1021/ol0480067] [Citation(s) in RCA: 384] [Impact Index Per Article: 19.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
2,5-Disubstituted oxazoles are synthesized from the corresponding propargylcarboxamides under mild reaction conditions via homogeneous catalysis by AuCl(3). While monitoring the conversion via (1)H NMR spectroscopy, an intermediate 5-methylene-4,5-dihydrooxazole can be observed and accumulated up to 95%, being the first direct and catalytic preparative access to such alkylidene oxazolines. The intermediate was fully characterized and can be trapped at -25 degrees C for several weeks. Deuteration experiments show a stereospecific mode of the two first steps of the reaction.
Collapse
Affiliation(s)
- A Stephen K Hashmi
- Institut für Organische Chemie, Universität Stuttgart, Pfaffenwaldring 55, D-70569 Stuttgart, Germany.
| | | | | | | |
Collapse
|
36
|
Vasquez TE, Nixey T, Chenera B, Gore V, Bartberger MD, Sun Y, Hulme C. One-pot microwave assisted preparation of pyrazoloquinazolinone libraries. Mol Divers 2004; 7:161-4. [PMID: 14870845 DOI: 10.1023/b:modi.0000006917.06401.48] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
The novel solution-phase synthesis of an array of biologically relevant pyrazoloquinazolinones in a simple microwave driven one pot procedure is revelaed. Transformations are carried out in good to excellent yield by condensation of alpha-cyano-ketones and 2-hydrazino-benzoic acids. Subsequent microwave irradiation affords pyrazoloquinazolinones with six points of potential diversification. The protocol described represents a very attractive solution phase procedure for the rapid generation of arrays of such functionalized cores, further demonstrating the growing importance of economic and enabling complexity generating chemistries in the lead discovery arena.
Collapse
Affiliation(s)
- Thomas E Vasquez
- Medicinal Chemistry Technologies, Chemistry Research and Development, AMGEN, One AMGEN Center Drive, Thousand Oaks, CA 91320, USA
| | | | | | | | | | | | | |
Collapse
|
37
|
Santagada V, Frecentese F, Perissutti E, Cirillo D, Terracciano S, Caliendo G. A suitable 1,2,4-oxadiazoles synthesis by microwave irradiation. Bioorg Med Chem Lett 2004; 14:4491-3. [PMID: 15357978 DOI: 10.1016/j.bmcl.2004.06.048] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2004] [Revised: 06/07/2004] [Accepted: 06/16/2004] [Indexed: 10/26/2022]
Abstract
One pot microwave-assisted synthesis of substituted 1,2,4-oxadiazoles in solvent and under solvent free condition was performed exploring the importance of some coupling reagents. Good yields and short reaction times were the main aspects of the methods.
Collapse
Affiliation(s)
- Vincenzo Santagada
- Dipartimento di Chimica Farmaceutica e Tossicologica, Università di Napoli 'Federico II', Via D. Montesano, 49, 80131 Naples, Italy.
| | | | | | | | | | | |
Collapse
|
38
|
Efficient one-pot synthesis of tryptamines and tryptamine homologues by amination of chloroalkynes. Tetrahedron Lett 2004. [DOI: 10.1016/j.tetlet.2004.02.085] [Citation(s) in RCA: 102] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
39
|
|
40
|
Logé C, Siomboing X, Wallez V, Scalbert E, Bennejean C, Cario-Tourmaniantz C, Loirand G, Gressier B, Pacaud P, Luyckx M. Synthesis and pharmacological study of Rho-kinase inhibitors: pharmacomodulations on the lead compound Fasudil. J Enzyme Inhib Med Chem 2003; 18:127-38. [PMID: 12943196 DOI: 10.1080/1475636031000093561] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
Abstract
With a view to specifying structure-activity relationships we have synthesised a new series of analogues of the Rho-kinase inhibitor 1-(5-isoquinolinesulfonyl)-homopiperazine (Fasudil). The structural modifications concerned the isoquinolinyl heterocycle and the sulfonyl group which are the two main features of this lead compound. These analogues were evaluated on the actin cytoskeleton and on the enzymatic activity of Rho-kinase. Most of the chemical modifications result in a loss of activity showing that interactions of Fasudil with the catalytic domain of Rho-kinase seem to be particularly definite and sensitive to structural variations. The presence of an isoquinolinyl nitrogen and a basic amino group separated by a spacer bearing a sulfonamide function are of utmost importance. Only the tetra-hydroisoquinoline analogue 3 shows the same activity as Fasudil. Moreover, this compound is unable to inhibit PKC biological activity contrary to Fasudil. The loss of the aromatic property could increase the selectivity level in favour of compound 3.
Collapse
Affiliation(s)
- Cédric Logé
- Faculté des Sciences Pharmaceutiques et Biologiques, BP 83, 59006 Lille Cedex, France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Yamada F, Tamura M, Hasegawa A, Somei M. Synthetic studies of psilocin analogs having either a formyl group or bromine atom at the 5- or 7-position. Chem Pharm Bull (Tokyo) 2002; 50:92-9. [PMID: 11824592 DOI: 10.1248/cpb.50.92] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Psilocin analogs having either a formyl group (9-12) or a bromine atom (13-18) at the 5- or 7-position have been prepared for the first time. Syntheses of 5- and 7-bromo derivatives of 4-hydroxy- (23, 24, 28) and 4-benzyloxyindole-3-carbaldehyde (19, 25, 29, 30), 4-benzyloxyindole-3-acetonitriles (20, 31), and 4-benzyloxy-N,N-dimethyltryptamine (32, 34, 35) have also been established.
Collapse
Affiliation(s)
- Fumio Yamada
- Faculty of Pharmaceutical Sciences, Kanazawa University, Japan
| | | | | | | |
Collapse
|
42
|
Russell MG, Baker RJ, Barden L, Beer MS, Bristow L, Broughton HB, Knowles M, McAllister G, Patel S, Castro JL. N-Arylsulfonylindole derivatives as serotonin 5-HT(6) receptor ligands. J Med Chem 2001; 44:3881-95. [PMID: 11689074 DOI: 10.1021/jm010943m] [Citation(s) in RCA: 85] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
A series of N(1)-arylsulfonyltryptamines were found to be potent ligands of the human serotonin 5-HT(6) receptor with the 5-methoxy-1-benzenesulfonyl analogue (19) having the highest affinity. Additionally, it was discovered that a group such as 3-(3-methoxybenzyl)-1,2,4-oxadiazol-5-yl in the 2-position of the indole ring (43) can replace the arylsulfonyl substituent in the 1-position with no loss of affinity. This suggested that the binding conformation of the aminoethyl side chain at this receptor was toward the 4-position of the indole ring and was supported by the fact that the 4-(aminoethyl)indoles (45) also displayed high affinity, as did the conformationally rigid 1,3,4,5-tetrahydrobenz[c,d]indole (49). Molecular modeling showed that 19, 43, and 45 all had low-energy conformers that overlaid well onto 49. Both 19 and 49 had good selectivity over other serotonin receptors tested, with 49 also showing excellent selectivity over all dopamine receptors. In a functional adenylate cyclase stimulation assay, 19 and 49 had no agonist activity, whereas 45 behaved as a partial agonist. Finally, it was shown that 19 had good activity in the 5-HT(2A) centrally mediated mescaline-induced head twitch assay, which implies that it is brain-penetrant.
Collapse
Affiliation(s)
- M G Russell
- Merck Sharp & Dohme Research Laboratories, Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR, United Kingdom.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
|
44
|
Abstract
A study of our database of 7,000 QSARs involving chemical-biological interaction uncovered 11 examples where the QSARs all contain inverted parabolas based on molecular refractivity. That is, biological activity first decreases with increase in MR and then increases. Two of the examples are for enzymes: cyclooxygenase and trypsin. The others are for various receptors. The results seem to be best rationalized by the larger compounds inducing a change in a receptor unit that allows for a new mode of interaction.
Collapse
Affiliation(s)
- C Hansch
- Department of Chemistry, Pomona College, Claremont, CA 91711, USA
| | | | | |
Collapse
|
45
|
Blair JB, Kurrasch-Orbaugh D, Marona-Lewicka D, Cumbay MG, Watts VJ, Barker EL, Nichols DE. Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines. J Med Chem 2000; 43:4701-10. [PMID: 11101361 DOI: 10.1021/jm000339w] [Citation(s) in RCA: 91] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
A series of fluorinated analogues of the hallucinogenic tryptamines N,N-diethyltryptamine (DET), 4-hydroxy-N,N-dimethyltryptamine (4-OH-DMT, psilocin), and 5-methoxy-DMT was synthesized to investigate possible explanations for the inactivity of 6-fluoro-DET as a hallucinogen and to determine the effects of fluorination on the molecular recognition and activation of these compounds at serotonin receptor subtypes. The target compounds were evaluated using in vivo behavioral assays for hallucinogen-like and 5-HT(1A) agonist activity and in vitro radioligand competition assays for their affinity at 5-HT(2A), 5-HT(2C), and 5-HT(1A) receptor sites. Functional activity at the 5-HT(2A) receptor was determined for all compounds. In addition, for some compounds functional activity was determined at the 5-HT(1A) receptor. Hallucinogen-like activity, evaluated in the two-lever drug discrimination paradigm using LSD-trained rats, was attenuated or abolished for all of the fluorinated analogues. One of the tryptamines, 4-fluoro-5-methoxy-DMT (6), displayed high 5-HT(1A) agonist activity, with potency greater than that of the 5-HT(1A) agonist 8-OH-DPAT. The ED(50) of 6 in the two-lever drug discrimination paradigm using rats trained to discriminate the 5-HT(1A) agonist LY293284 was 0.17 micromol/kg, and the K(i) at [(3)H]8-OH-DPAT-labeled 5-HT(1A) receptors was 0.23 nM. The results indicate that fluorination of hallucinogenic tryptamines generally has little effect on 5-HT(2A/2C) receptor affinity or intrinsic activity. Affinity at the 5-HT(1A) receptor was reduced, however, in all but one example, and all of the compounds tested were full agonists but with reduced functional potency at this serotonin receptor subtype. The one notable exception was 4-fluoro-5-methoxy-DMT (6), which had markedly enhanced 5-HT(1A) receptor affinity and functional potency. Although it is generally considered that hallucinogenic activity results from 5-HT(2A) receptor activation, the present results suggest a possible role for involvement of the 5-HT(1A) receptor with tryptamines.
Collapse
MESH Headings
- 3T3 Cells
- Animals
- Binding, Competitive
- CHO Cells
- Colforsin/pharmacology
- Cricetinae
- Cyclic AMP/biosynthesis
- Discrimination Learning/drug effects
- Drug Evaluation, Preclinical
- Fluorine/chemistry
- Hallucinogens/chemical synthesis
- Hallucinogens/chemistry
- Hallucinogens/pharmacology
- Humans
- Hydrolysis
- Mice
- Phosphatidylinositols/metabolism
- Radioligand Assay
- Rats
- Receptor, Serotonin, 5-HT2A
- Receptor, Serotonin, 5-HT2C
- Receptors, Serotonin/metabolism
- Receptors, Serotonin/physiology
- Receptors, Serotonin, 5-HT1
- Serotonin Receptor Agonists/chemical synthesis
- Serotonin Receptor Agonists/chemistry
- Serotonin Receptor Agonists/pharmacology
- Structure-Activity Relationship
- Tryptamines/chemical synthesis
- Tryptamines/chemistry
- Tryptamines/pharmacology
Collapse
Affiliation(s)
- J B Blair
- Department of Medicinal Chemistry and Molecular Pharmacology, School of Pharmacy and Pharmacal Sciences, Purdue University, West Lafayette, Indiana 47907, USA
| | | | | | | | | | | | | |
Collapse
|
46
|
Cocquet G, Ferroud C, Guy A. A Mild and Efficient Procedure for Ring-Opening Reactions of Piperidine and Pyrrolidine Derivatives by Single Electron Transfer Photooxidation. Tetrahedron 2000. [DOI: 10.1016/s0040-4020(00)00048-x] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
|
47
|
Barf T, Wikström H, Pauwels PJ, Palmier C, Tardif S, Lundmark M, Sundell S. 5-(Sulfonyl)oxy-tryptamines and ethylamino side chain restricted derivatives. Structure-affinity relationships for h5-HT1B and h5-HT1D receptors. Bioorg Med Chem 1998; 6:1469-79. [PMID: 9801818 DOI: 10.1016/s0968-0896(98)00079-0] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
A number of sulfonic acid ester derivatives of serotonin (5-hydroxytryptamine; 5-HT; 1) were prepared and their affinities are compared to that of the reference compound 5-[[(trifluoromethyl)sulfonyl]oxy]-tryptamine (8b). The structure-affinity relationship (SAFIR) is discussed in terms of in vitro binding for cloned human h5-HT1A, h5-HT1B and h5-HT1D receptors. All tryptamine derivatives exhibited the best affinities for h5-HT1D receptors but still, these were comparatively lower than that of compound 8b. 5-Tosylated tryptamine 11b (Ki = 6 nM) and the sulfamate derivatives 13b and 14b (Ki = 7 and 11 nM, respectively) were found to have the highest affinities for the h5-HT1D receptor. Other tryptamine derivatives displayed moderate binding for h5-HT1A and h5-HT1B receptors, along with Ki values ranging from 14-20 nM for the h5-HT1D sites. In addition, the syntheses of two alkylamino side chain restricted derivatives are described. 3-Amino-6-[[(trifluoromethyl)sulfonyl]oxy]-1,2,3,4-tetrahydrocarbazol e 21, as well as 4-[5-[[(trifluoromethyl)sulfonyl]oxy]-1H-indol-3-yl]piperidines 24 and 25, induced a shift in selectivity in favor of the h5-HT1B receptor. The relatively longer distance between the basic amine and a hydrogen-bond accepting oxygen in 21, 24 and 25 as compared to the non-restricted tryptamines, is likely responsible for this observation.
Collapse
Affiliation(s)
- T Barf
- Department of Medicinal Chemistry, University of Groningen, The Netherlands.
| | | | | | | | | | | | | |
Collapse
|
48
|
Mlakar B, Štefane B, Kočevar M, Polanc S. Carboxamide oximes as convenient precursors for the synthesis of pyrimidine N-oxides. Tetrahedron 1998. [DOI: 10.1016/s0040-4020(98)00152-5] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
49
|
Moloney GP, Robertson AD, Martin GR, MacLennan S, Mathews N, Dodsworth S, Sang PY, Knight C, Glen R. A novel series of 2,5-substituted tryptamine derivatives as vascular 5HT1B/1D receptor antagonists. J Med Chem 1997; 40:2347-62. [PMID: 9240350 DOI: 10.1021/jm9605849] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
The design, synthesis, and activity of a novel series of 2,5-substituted tryptamine derivatives at vascular 5HT1B-like receptors is described. Several important auxiliary binding sites of the 5HT1B-like receptor have been proposed following various modifications to the 2-substituent and especially to the methylene- or ethylene-linked 5-side chain. Careful design of new molecules based on a proposed pharmacophoric model of the 5HT1B-like receptor has resulted in the discovery of ethyl 3-[2-(dimethylamino)ethyl]-5-[2-(2, 5-dioxo-1-imidazolidinyl)ethyl]-1H-indole-2-carboxylate (40), a highly potent, silent, competitive, and selective antagonist which shows affinity at the vascular 5HT1B-like receptors only. Changes to the size of the 2-ester substituent have a significant effect on affinity at the 5HT1B-like receptor and other receptors. Prudent placement of the carbonyl substituent in the heterocycle of the 5-side chain is crucial for good affinity and selectivity over the 5HT2A and other receptors. Several key structural and electronic features were identified which are crucial for producing antagonism within a tryptamine-based series. An electron deficient indole ring system appears essential in order to achieve antagonism, and this is achieved by the inclusion of electron-withdrawing groups at the 2-position of the indole ring. The molecule displacement within the receptor resulting from the inclusion of the bulky 2-substituents also enhances antagonism as this results in the removal of the pi electron density of the indole ring from the region of the receptor normally occupied by the indole ring of 5HT. There also appears to be a structural requirement on the side chain incorporating the protonatable nitrogen, and this is achieved by the inclusion of the bulky 2-ester group which neighbors the 3-ethylamine side chain.
Collapse
Affiliation(s)
- G P Moloney
- Department of Medicinal Chemistry, Victorian College of Pharmacy, Monash University, Parkville, Australia
| | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Synthesis, binding affinity and intrinsic activity of new anilide derivatives of serotonin at human 5-HT1D receptors. Eur J Med Chem 1997. [DOI: 10.1016/s0223-5234(97)87539-3] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|